Serum Tumor Marker Carbohydrate Antigen 19-9 For The Diagnosis And Prognosis Of Pancereatic Cancer

Objective To evaluate serum tumor marker carbobydrate antigen 19-9 (CA19-9) for the diagnosis and prognosis of pancreatic cancer. Patients and Methods Serum CA19-9 levels were determined gerially electrochemilu minescene in 132 patients with pancreatic cancer coming from West china hospital and Sichuan province people's hospital from jan 2001 to jan 2004. Routine preoperative examinations in all patients with pancreatic carcinomas consist of ultrasonography, CT-scan of the abdomen and MRI; clinical courses with respect to the pathological data, surgical procedures employed and the prognosis of these patients were evaluate prospectively. Results Serum CA19-9 level 589±502.21 and the positive rate 87.12% in 132 patients with pancreatic cancer were significantly higher than that of healthy people. With hyposerum CA19-9 (CA19-9＞200 u/ml) level group for the metastasis rate of pancreatic carcinoma and operation resection rate were no significant relation with the lower-serum (CA19-9≤200u/ml) CA19-9 level group. There were no significant relations between the serum CA19-9 level and clinicopathological features of pancreatic cancer such as the age, sex, smoking history, differentiation and location. The serum CA19-9 level had significant relations with the stage, size and histological classification of tumor. Conclusion Serum CA19-9 may be of useful tumor maker for diagnosis of pancreatic carcinoma, prediction of the prognosis of the patients after resection. The serum CA19-9 has no much useful for guiding the surgical operation and were be influenced by the stage, size and histological classification of tumor.